Inst. Holders
1 funds
VCNX
VACCINEX, INC.
$1.01 ▼ -1.94%
Prev close $1.03 Biotech & Drug Discovery
Snapshot
The big-picture read on VCNX right now — valuation, ownership and activity at a glance.
Inst. Value
$92.00
Inst. Activity
1 buys / 0 sells
SEC Reports
1
Price chart 30d +1.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Apr 30, 2026 SEC
Vaccinex released financial results for the year ended December 31, 2025, reporting an EPS of -$1.09 for Q3 2023, which
PRESS-RELEASE — Impact 3/10
Apr 30, 2026 earnings
Vaccinex Reports 2025 Annual Financial Results
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage
Dec 31, 2024 Inst.
BARCLAYS PLC — ADD
46 shares (—)
Sep 30, 2024 Inst.
Point72 Asset Management, L.P. — ADD
166,000 shares ($564.4K)
Analyst ratings buy % +14.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Nov 1, 2021 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Oct 1, 2021 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Sep 1, 2021 | 3 | 3 | 2 | 0 | 0 | 75% |
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
1 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 3.0/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Apr 30, 2026
earnings
Vaccinex Reports 2025 Annual Financial Results
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneer
Mar 30, 2026
earnings_calendar
VCNX Q4 2025 Earnings Scheduled — 2026-03-30
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Institutional ownership
Which big funds own VCNX (from quarterly 13F filings) and who is adding or trimming.
1 institutional holders with $92.00 total value (27 shares) as of 2025-Q3. Top holders: BARCLAYS.
Top holders — 2025-Q3
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BARCLAYS PLC | 27 | $92.00 | 100.0% | ADD +70.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BARCLAYS PLC | ADD | 27 | 46 | +70.4% | — |
| Point72 Asset Management, L.P. | ADD | 116,546 | 166,000 | +42.4% | $564.4K |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 8 | 24 | +200.0% | $82.00 |
| MORGAN STANLEY | NEAR_EXIT | 1,113 | 4 | -99.6% | $14.00 |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VCNX.
Shares short
2,593
Settlement Sep 15, 2026
Change vs prior
-4.6%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
All VCNX filing & press-release reports (1)
- PRESS-RELEASE reportApr 30, 2026